Supplementary Table 3 from Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
Rongrong WeiGuoliang HuangMei‐Yin ZhangBinkui LiHuizhong ZhangMing ShiXiaoqian ChenLong HuangQingming ZhouWei‐Hua JiaX.F. Steven ZhengYunfei YuanHui‐Yun Wang
0
Citation
0
Reference
10
Related Paper
Abstract:
<p>PDF file, 132K, Differential expression of miRNAs between clinical features.</p>Keywords:
Value (mathematics)
Expression (computer science)
Table (database)
Clinical Significance
Abstract Background : MicroRNAs are noncoding RNAs that regulate cellular processes during the progression of tumors. Among various microRNAs, MicroRNA-154 ( miR-154 ) has been reported to be involved in many critical processes of human malignancies. This study aimed to evaluate the significance and prognostic value of miR-154 in human non-small cell lung cancer (NSCLC). Methods : A total of 144 NSCLC tissues samples and matched non-tumor adjacent tissues specimens were obtained from NSCLC patients and the quantitative real-time PCR (qRT-PCR) was performed to investigate expression levels of miR-154 . The correlation between miR-154 expression and survival outcomes of NSCLC patients was performed by Kaplan-Meier analysis, univariate and multivariate analysis. Results : MiR-154 expression was significantly decreased in NSCLC tissues compared with that in matched non-tumor adjacent tissues ( P <0.001). In addition, low expression of miR-154 was demonstrated to be associated with tumors size, TNM stages and distant metastasis of NSCLC patients Survival analysis revealed that patients with low expression of miR-154 showed significantly lower survival rate for OS, DFS and RFS, respectively (all, log rank test, P <0.001) and miR-154 could be an independent prognostic indicator for NSCLC patients. Conclusion : The results suggest that miR-154 has the clinical significance in the progression of NSCLC and could be a potential prognostic biomarker for NSCLC patients.
Clinical Significance
Univariate analysis
Cite
Citations (0)
MicroRNAs (miRNAs) are approximately 22-nucleotide noncoding RNAs that constitute silencers of target gene expression and have emerged as key regulatory molecules of mammalian cell functions. Aberrant miRNA expression promotes pathologic conditions including hepatocellular carcinoma (HCC) and a variety of precancerous liver diseases, especially chronic hepatitis B and C, and liver cirrhosis. miRNAs may contribute to HCC development by acting as oncogenes or tumor suppressors. Specific alterations of miRNA expression have also been related to clinical features of HCC, such as stage, differentiation, prognosis, and response to adjuvant therapy. miRNA signatures may help define molecular profiles of liver diseases as biomarkers, and allow classification of different stages of cirrhosis and HCC progression. Either miRNAs, or anti-miRNA oligonucleotides (antagomirs) could be used for in vivo modulation of miRNA actions, and thus have significant potential in molecularly targeted therapy. Keywords: microRNA, hepatocellular carcinoma, liver diseases, noncoding RNAs, silencers, gene expression, oncogenes, tumor suppressors, antagomirs, targeted therapy
Liver Cancer
Cite
Citations (2)
Background: Hepatitis C virus (HCV) is a major global healthcare problem.The WHO estimates that up to 3% of the world's population has been infected with the virus, equating to more than 170 million individuals worldwide, with significant associated morbidity and mortality.Objective: The aim of this study was to detect effect of treating chronic hepatitis C infection with direct-acting antivirals on the risk of recurrence hepatocellular carcinoma.Subjects and methods: This prospective study included a total of 150 patients with compensated chronic hepatitis C virus infection and 150 patients with compensated chronic hepatitis C virus infection with prior history of treated hepatocellular carcinoma by ablation, resection, chemoembolization or liver transplantation, attending at Viral Hepatitis Units, Departments of Internal Medicine, Assiut and Aswan University Hospitals.This study was conducted between December 2017 and December 2019.Results: The present study shows that 33.3% of HCC had history of treatment with surgical resection, 46.7% had history of Radiofrequency ablation (RFA), 13.3% of Transarterial Chemoembolization (TACE) and 6.7% with liver transplantation.There were highly significant differences between the two studied groups as regard ALT, total bilirubin, creatinine and AFP levels.There were no significant differences between the two studied groups as regard albumin, INR, platelets, total protein and WBCs.There were no significant differences between the studied groups as regard Hepatocellular carcinoma "occurrence or recurrence" and time needed for HCC to occur after direct-acting antiviral agents (DAAs).Conclusion: It could be concluded that antiviral treatment should not be delayed in hepatocellular carcinoma patients in order to avoid further liver deterioration and extrahepatic complications of HCV.
Hepatitis C
Cite
Citations (0)
Background: Egypt had been vexed by the highest load of chronic hepatitis C in the world.It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Objectives:The aim of this study is to detect the occurrence and recurrence of hepatocellular carcinoma (HCC) during the follow-up after antiviral treatment with direct acting antiviral therapy in patients with chronic HCV infection and in patient with chronic HCV prior history of treated hepatocellular carcinoma who achieved complete response.Subjects and methods: This was prospective study including 150 patients with compensated chronic hepatitis C virus infection and 150 patients with compensated chronic hepatitis C virus infection prior history of treated hepatocellular carcinoma.The patients were attending Aswan university hospital and viral hepatitis unit in addition to Viral Hepatitis Unit and were prospectively collected at the end of December 2019.The patients were divided into two groups: Group (A): patients with chronic HCV infection who were treated with direct acting antivirals.Group (B): patients with chronic HCV infection prior history of treated hepatocellular carcinoma who were treated with direct acting antivirals. Results:The results of the study revealed that there was no significant difference between the studied groups as regard time needed for HCC to occur after DAA.Conclusion: Surveillance programs should be widely endorsed during and after DAAs therapy for patients at HCC risk, even for those who had been achieved HCV cure.
Cite
Citations (0)
MicroRNAs (miRNAs) are small endogenous noncoding RNAs that were shown to be essential posttranscriptional regulators of gene expression. MiRNAs most notably members of the miR–34 family, have been shown to be subject to transcriptional regulation by wild-type p53. We have established a relevant role for the p53 family in the induction of apoptosis, therapeutic response and prognosis of hepatocellular carcinoma (HCC). TAp73–like wild-type p53- is a mediator of apoptosis. The dominant negative isoform of p73 (DNp73)–on the contrary–is antiapoptotic and enhanced expression of DNp73 correlates with reduced survival of HCC patients.
Identification
Cite
Citations (0)
Objective
To observe the expression of microRNA (miRNA, miR)-chr1011 in hepatocellular carcinoma (HCC) tissues and analyze its clinical significance in HCC patients.
Methods
High-throughput deep sequencing was used to analyze the small RNA sequences in 6 pairs of HCC tissues. Data of deep sequencing were compared with the gene database to predict novel miRNAs by miRdeep 2.0.0.5 software. Northern blot was utilized to verify the structure and authenticity of the novel miRNAs. The expression levels of novel miRNAs in 62 pairs of HCC tissues were detected by Real-time quantitative polymerase chain reaction (RT-qPCR) and the clinical data of HCC patients were analyzed.
Results
MiR-chr1011 was found in human liver tissues and liver cancer cell lines, which has a stable precursor structure and is located on human chromosome chr10.11: 107803675-107803737: + . Northern blot assay confirmed its expression in HCCLM3 and Huh7 liver cancer cells. In 62 pairs of HCC tissues, the expression of miR-chr1011 in tumor adjacent tissues was higher than tumor tissues (4.37±0.31 vs. 2.81±0.21, P< 0.01), and the expression of miR-chr1011 was negatively correlated with the Barcelona stage of tumor (P<0.01), TNM stage (P<0.01) and portal vein thrombosis (PVTT) formation (P<0.05).
Conclusion
MiR-chr1011 is lowly expressed in liver cancer tissues and is significantly associated with the prognosis of HCC patients.
Key words:
Carcinoma, hepatocellular; MicroRNA-chr1011
Liver Cancer
Clinical Significance
Northern blot
Cite
Citations (0)
Objective To investigate the abnormal expression of microRNAs (miR-216,miR-222,miR-181) in the serum of patients with hepatocellular carcinoma (HCC) and its clinical significance.Methods Serum miRNAs expression was investigated in 49 patients with HCC and 25healthy normal controls by using real-time PCR technique,and then correlations between miRNAs expression
Clinical Significance
Cite
Citations (0)
Objective
To detect the profile of 114 microRNA (miRNA) expression in hepatocellular carcinoma and investigate the relationship of miR-338 expression with clinicopathological parameters.
Methods
A bead-based miRNA expression profiling method was performed on 20 pairs of surgically removed HCC and adjacent non-tumorous tissue (NT). Special miR-338 downregulations and miR-338 associated with clinical characteristics was validated in an extended samples set of 36 paired HCC and adjacent non-tumorous liver tissues by real-time reverse transcription polymerase chain reaction (RT-PCR) analysis.
Results
Among these 114 miRNA, 31 miRNA were differentially expressed between HCC and non-cancerous liver tissues with 12 miRNA upregulated and 19 miRNA downregulated in HCC. The downexpression levels of miR-338 cases were found to be significantly associated with vascular invasion, intrahepatic metastasis, tumor size and tumor grade. However, there was no significant difference between miR-338 expression and other clinicopathological parameters in HCC. miR-338 was chosen for expression analysis by real-time RT-PCR analysis in an additional independent set of 36 pairs of HCC and NT. The results showed that the mRNA expression level of miR-338 in HCC was lower than in NT (P < 0.01), the mRNA expression level of miR-338 in M was lower than in NM (P < 0.01) and decreased miR-338 expression was correlated with increasing stage of HCC (P < 0.01).
Conclusion
Our study suggests that miR-338 expression could have relevance to the clinical behavior of HCC.
Key words:
Hepatocellular carcinoma; MicroRNA; miR-338; Metastasis
Clinical Significance
Cite
Citations (0)
Cite
Citations (0)
选取手术后原发性肝癌（HCC）组织标本90例（HCC组）、癌旁组织45例（对照组），采用实时荧光定量PCR技术（RT-PCR）检测两组标本中的miRNA-29a表达水平。结果显示HCC组的微小RNA-29a（miRNA-29a）表达低于对照组（P 400 ng/ml、发生血管浸润的HCC组织miRNA-29a表达低于TNM分期（Ⅰ+Ⅱ）、高+中分化、术前AFP≤400 ng/ml、未发生血管浸润的HCC组织（P < 0.05）；miRNA-29a高表达组的中位生存时间16.0个月高于低表达组的11.0个月（P < 0.05）。HCC组织miRNA-29a表达水平显下调，可能与肿瘤恶性程度、不良预后有关。.
Clinical Significance
Cite
Citations (0)